Para-aminosalicylic acid: The return of an old friend

The Lancet Infectious Diseases

Volumn 15, Issue 9, 2015, Pages 1091-1099

  Donald, Peter R ^a   Diacon, Andreas H ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ISONIAZID; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL FEATURE; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERANCE; ELIMINATION RATE CONSTANT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FIRST PASS EFFECT; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SLOW RELEASE FORMULATION; TUBERCULOSIS CONTROL; VOMITING; DRUG DEVELOPMENT; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; MEDICINAL CHEMISTRY; TUBERCULOSIS, PULMONARY;

AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TUBERCULOSIS, PULMONARY;

EID: 84940778507     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00263-7     Document Type: Review

References (80)

1. PAS. Tubercle 1973, 54:165-167. Anonymous.
2. Fox W, Sutherland I A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med 1956, 25:221-243.
3. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010, 375:1798-1807.
4. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014, 383:1230-1239.
5. m Aminosalicysäure. Monatsh Chem 1902, 23:431-433.
6. Lehmann J The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Dis Chest 1949, 16:684-703.
7. Lehmann J Twenty years afterward. Historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials. Am Rev Respir Dis 1964, 90:953-956.
8. Dubovsky H Correspondence with a pioneer, Jurgen Lehmann (1898-1989), producer of the first effective antituberculosis specific. S Afr Med 1991, 79:48-50.
9. Bernheim F The effect of salicylate on the oxygen uptake of the tubercle bacillus. Science 1940, 92:204.
10. Lehmann J Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946, 1:15.
11. Bogen E, Loomis RN, Will DW Para-aminosalicylic acid treatment of tuberculosis; a review. Am Rev Tuberc 1950, 61:226-246.
12. Para-aminosalicylic acid treatment in pulmonary tuberculosis. Am Rev Tuberc 1950, 61:597-612. The Therapeutic Trials Committee of the Swedish National Association against tuberculosis.
13. Citron KM, Kuper SW Para-aminosalicylic-acid (PAS) concentrations in the serum during treatment with various PAS preparations. Tubercle 1959, 40:443-452.
14. Hollander AG Para-aminosalicylic acid-resin complex: studies in absorption, serum electrolytes, and tolerance. Am Rev Tuberc 1955, 72:548-551.
15. Lewis DO Drug resistance in pulmonary tuberculosis treated with calcium B-PAS. Tubercle 1958, 39:247-250.
16. Yue WY, Cohen SS Toleration and absorption of sodium para-aminosalicylate and para-aminosalicylic acid (neopasalate). Comparison with other forms of para-aminosalicylic acid. Dis Chest 1966, 49:165-174.
17. Jones JS Intravenous P.A.S. in relation to pulmonary tuberculotherapy, with an account of 1,145 transfusions. Br J Tuberc Dis Chest 1954, 48:286-297.
18. Lehmann J The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand J Respir Dis 1969, 50:169-185.
19. Wan SH, Pentikainen PJ, Azarnoff DL Bioavailability of aminosalicylic acid and its various salts in humans. 3. Absorption from tablets. J Pharm Sci 1974, 63:708-711.
20. Kibleur Y, Brochart H, Schaaf HS, Diacon AH, Donald PR Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis. Clin Drug Investig 2014, 34:269-276.
21. Carstensen B Para-aminosalicylic acid (PAS) in pulmonary and extrapulmonary tuberculosis. Am Rev Tuberc 1950, 61:613-620.
22. Kallqvist I Para-aminosalicylic acid therapy in intestinal tuberculosis. Am Rev Tuberc 1950, 61:621-642.
23. Vallentin G, Tornell E, Bescow A, et al. p-Amino-salicylic acid in pulmonary tuberculosis. Tubercle 1950, 31:2-10.
24. Dempsey TG, Logg MH Para-aminosalicylic acid in tuberculosis; early results of clinical trials. Lancet 1947, 2:871.
25. Erdei A Pulmonary tuberculosis treated with p-aminosalicylic acid; early results in six cases. Lancet 1948, 1:791-793.
26. Feldman WH, Karlson AG, Carr DT, Hinshaw HC Parenteral administration of p-aminosalicylic acid in experimental tuberculosis. Proc Staff Meet Mayo Clin 1949, 24:220-224.
27. Pfuetze KH, Pyle MM Chemotherapy in clinical tuberculosis. Proc Staff Meet Mayo Clin 1949, 24:213-219.
28. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid; a Medical Research Council investigation. BMJ 1950, 2:1073-1085. Medical Reseach Council.
29. Prevention of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation. BMJ 1952, 1:1157-1162. Medical Research Council.
30. Daniels M, Hill AB Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials. BMJ 1952, 1:1162-1168.
31. Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their tuberculosis Chemotherapy Trials Committee. BMJ 1952, 2:735-746. Medical Research Council.
32. Isoniazid in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their tuberculosis Chemotherapy Trials Committee. BMJ 1953, 2:1005-1014. Medical Research Council.
33. Isoniazid in the treatment of pulmonary tuberculosis; second report to the Medical Research Council by their tuberculosis Chemotherapy Trials Committee. BMJ 1953, 1:521-536. Medical Research Council.
34. Various combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council by their tuberculosis Chemotherapy Trials Committee. BMJ 1955, 1:435-445. Medical Research Council.
35. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948, 2:769-782. Medical Research Council.
36. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
37. Furin J The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007, 13:212-217.
38. Guidelines for the programmatic management of drug-resistant tuberculosis World Health Organization, (accessed May 15, 2014). http://wwwwhoint/tb/publications/2011/en/indexhtml%202011.
39. Marsden JA The single daily dose of sodium para-aminosalicylic acid used in conjunction with streptomycin in tuberculosis. Med J Aust 1954, 2:934-935.
40. Bridge EV, Carr DT, Karlson AG. The effect of a single daily dose of NaPAS on the emergence of streptomycin-resistant strains of tubercle bacilli. 12th Conference on the Chemotherapy of tuberculosis; Atlanta, GA, USA; Feb 9-12, 1953. 209-15.
41. Bridge EV, Carr DT Clinical use of a single daily dose of para-aminosalicylic acid in association with isoniazid. Am Rev Tuberc 1958, 78:749-752.
42. Singh B, Mitchison DA Bactericidal activity of streptomycin and isoniazid in combination with p-aminosalicylic acid against Mycobacterium tuberculosis. J Gen Microbiol 1955, 12:76-84.
43. Youmans GP, Youmans AS The assessment of antituberculous chemotherapeutic activity in mice, using virulent human-type tubercle bacilli. Am Rev Tuberc 1951, 64:541-550.
44. McKee CM, Donovick R, Rake G, Jambor WP The use of the mouse in a standardized test for antituberculous activity of compounds of natural or synthetic origin; the standardized test. Am Rev Tuberc 1949, 60:109-120.
45. Karslon AG, Carr DT Effect of single and of double daily doses of para-aminosalicylic acid in tuberculosis of guinea pigs. Am Rev Tuberc 1958, 78:753-759.
46. Jindani A, Aber VR, Edwards EA, Mitchison DA The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980, 121:939-949.
47. Mitchison DA Basic concepts in the chemotherapy of tuberculosis. Mycobacteria II-Chemotherapy 1998, 15-50. Chapman & Hall, New York, NY. P.R.J. Gangadharam, P.A. Jenkins (Eds.).
48. Mitchell RS, Schmidt J, Capel LH, Scheel L Study of para-aminosalicylic acid intolerance in tuberculosis of lung. JAMA 1954, 156:124.
49. Riska N Variations in the PAS concentration in the blood and their influence on treatment of tuberculosis. Acta Tuberc Pneumol Scand 1954, 30:144-163.
50. Riska N PAS therapy with a daily unfractionated dose. Acta Tuberc Pneumol Scand 1959, 37:104-111.
51. Riska N, Tennberg C Optimal PAS dosage. Am Rev Respir Dis 1962, 86:430-433.
52. Wilson JL, Lampe WT Single daily dose regimen of isoniazid and PAS in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1964, 89:756-759.
53. Bang HO, Strandgaard E Continued studies on the problems of PAS dosage. Acta Tuberc Pneumol Scand 1960, 39:81-96.
54. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999, 159:932-934.
55. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 1994, 14:40-46.
56. Sy SKB, de Kock L, Diacon AH, et al. N-acetyltrasferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother 2015, 59:4129-4138.
57. Mount FW, Ferebee SH United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and para-aminosalicylic acid. Am Rev Tuberc 1954, 70:521-526.
58. Berte SJ, Dimase JD, Christianson CS Isoniazid, para-aminosalicylic acid, and streptomycin intolerance in 1,744 patients. An analysis of reactions to single drugs and drug groups plus data on multiple reactions, type and time of reactions, and desensitization. Am Rev Respir Dis 1964, 90:598-606.
59. Phillips S Comparison of isoniazid alone with isoniazid-PAS in the original chemotherapy of noncavitary pulmonary tuberculosis. Results from the Veterans Administration-Armed Forces co-operative study on the chemotherapy of tuberculosis. Am Rev Respir Dis 1959, 80:641-647.
60. Berte SJ, Dewlett HJ Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS. Dis Chest 1959, 36:146-151.
61. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013, 8:e63057.
62. Iwainsky I Mode of action, biotransformation and pharmacokinetics. 1. PAS. Antituberculosis drugs 1988, 457-465. Springer Verlag, Berlin. K. Bartmann (Ed.).
63. Portwich F Untersuchung des Mechanismus der Nierenausscheidung von Arzneimitteln. Antibiot Chemother 1964, 12:41-52.
64. Lauener H, Favez G The inhibition of isoniazid inactivation by means of PAS and benzoyl-PAS in man. Am Rev Respir Dis 1959, 80:26-37.
65. Johnson W, Corte G Inhibition of isoniazid acetylation in vitro and vivo. Proc Soc Exp Biol Med 1956, 92:446-448.
66. Morse WC, Curry FJ, Morse PZ, Chambers JS, Lincoln AF Transactions of the 15th Conference on the Chemotherapy of tuberculosis. February 6th to 9th, 1956 1956, 283. US Government Printing Office, St. Louis, Missouri, Washington, DC.
67. Ragaz L Zur Pharmakologie der p-Aminosalicylsäure; Nachweis, Verteilung im Organismus und renale Elimination. Schweiz Med Wochenschr 1948, 78:1213-1219.
68. Way EL, Smith PK, Howie DL, Weiss R, Swanson R The absorption, distribution, excretion and fate of para-aminosalicylic acid. J Pharmacol Exp Ther 1948, 93:368-382.
69. Hanngren A Studies on the distribution and fate of C14-and T-labelled p-amino-salicylic acid (PAS) in the body. Acta Radiol Suppl 1959, 175:1-118.
70. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother 2001, 35:1332-1338.
71. Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation. J Trop Pediatr 2013, 59:90-94.
72. Hughes HB On the metabolic fate of isoniazid. J Pharmacol Exp Ther 1953, 109:444-452.
73. Motulsky AG, Steinmann L Arylamine acetylation in human red cells. J Clin Invest 1962, 41:1387.
74. Blum M, Grant DM, McBride W, Heim M, Meyer UA Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990, 9:193-203.
75. Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 1998, 8:55-66.
76. Grzybowski S, Enarson D Results in pulmonary tuberculosis patients under various treatment program conditions. Bull Int Union Tuberc 1978, 53:70-75.
77. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011, 6:e17601.
78. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, 33:871-881.
79. Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012, 16:90-97.
80. Crofton J Drug treatment of tuberculosis. I. Standard chemotherapy. BMJ 1960, 2:370-373.